Whole Genome Expression Profiling of Blood Cells in Ovarian Cancer Patients -prognostic Impact of the CYP1B1, MTSS1, NCALD, and NOP14

Overview

Journal Oncotarget

Specialty Oncology

Date 2014 Jun 26

PMID 24961659

Citations 24

Authors

Helena S Isaksson

Bengt Sorbe

Torbjorn K Nilsson

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer patients with different tumor stages and cell differentiation might be distinguished from each other by gene expression profiles in whole blood cell mRNA by the Affymetrix Human Gene 1.0 ST Array. We also examined if there is any association with other clinical variables, response to therapy, and residual tumor burden after surgery. Patients were divided into two groups, one with poor prognosis, advanced stage and poorly differentiated tumors (n = 22), and one group with good prognosis, early stage and well- to medium differentiated tumors (n = 11). Six genes were found to be differentially expressed: the PDIA3, LYAR, NOP14, NCALD and MTSS1 genes were down-regulated and the CYP1B1 gene expression was up-regulated in the poor prognosis group, all with p value <0.05, adjusted for mass comparison. In survival analyses, CYP1B1, MTSS1, NCALD and NOP14 remained significantly different (p<0.05). Patient groups did not differ in any transcript related to acute phase or immune responses. This minimal gene expression signature of prognostic ovarian cancer-related genes opens up an avenue for more practicable monitoring of ovarian cancer patients by simple peripheral blood tests, which may evolve into a tool to guide selection of curative and postoperative supportive therapies.

Citing Articles

Eslami M, Khazeni S, Mohammadi Khanaghah X, Asadi M, Ansari M, Garjan J Cancer Cell Int. 2023; 23(1):182.

PMID: 37635248 PMC: 10463971. DOI: 10.1186/s12935-023-03022-5.

The role of DNA methylation in ovarian cancer chemoresistance: A narrative review.

Song K, Artibani M Health Sci Rep. 2023; 6(5):e1235.

PMID: 37123549 PMC: 10140645. DOI: 10.1002/hsr2.1235.

Increased expression of NOP14 is associated with improved prognosis due to immune regulation in colorectal cancer.

Lu C, Liao W, Huang Y, Huang Y, Luo Y BMC Gastroenterol. 2022; 22(1):207.

PMID: 35473611 PMC: 9044756. DOI: 10.1186/s12876-022-02286-x.

Clinicopathological and prognostic significance of NCALD protein expression in lung adenocarcinoma.

Chen Y, Feng X, Shen H, Zhang L, Li X, Gao L Transl Cancer Res. 2022; 8(3):752-760.

PMID: 35116813 PMC: 8798630. DOI: 10.21037/tcr.2019.04.15.

LYAR Promotes Colorectal Cancer Progression by Upregulating Expression and Fatty Acid Metabolism.

Wu Y, Zhou Y, Gao H, Wang Y, Cheng Q, Jian S Oxid Med Cell Longev. 2022; 2021:9979707.

PMID: 35069968 PMC: 8769847. DOI: 10.1155/2021/9979707.

References

Downie D, McFadyen M, Rooney P, Cruickshank M, Parkin D, Miller I . Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res. 2005; 11(20):7369-75. DOI: 10.1158/1078-0432.CCR-05-0466. View

Martin L, Schilder R . Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol. 2007; 25(20):2894-901. DOI: 10.1200/JCO.2007.11.1088. View

Ross R, Galsky M, Scher H, Magidson J, Wassmann K, Lee G . A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol. 2012; 13(11):1105-13. DOI: 10.1016/S1470-2045(12)70263-2. View

Fu J, Zhang J, Jin F, Patchefsky J, Braunewell K, Klein-Szanto A . Promoter regulation of the visinin-like subfamily of neuronal calcium sensor proteins by nuclear respiratory factor-1. J Biol Chem. 2009; 284(40):27577-86. PMC: 2785686. DOI: 10.1074/jbc.M109.049361. View

Sissung T, Price D, Sparreboom A, Figg W . Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res. 2006; 4(3):135-50. DOI: 10.1158/1541-7786.MCR-05-0101. View

Haynes L, Fitzgerald D, Wareing B, OCallaghan D, Morgan A, Burgoyne R . Analysis of the interacting partners of the neuronal calcium-binding proteins L-CaBP1, hippocalcin, NCS-1 and neurocalcin delta. Proteomics. 2006; 6(6):1822-32. DOI: 10.1002/pmic.200500489. View

Su L, Hershberger R, Weissman I . LYAR, a novel nucleolar protein with zinc finger DNA-binding motifs, is involved in cell growth regulation. Genes Dev. 1993; 7(5):735-48. DOI: 10.1101/gad.7.5.735. View

Fu J, Fong K, Bellacosa A, Ross E, Apostolou S, Bassi D . VILIP-1 downregulation in non-small cell lung carcinomas: mechanisms and prediction of survival. PLoS One. 2008; 3(2):e1698. PMC: 2246032. DOI: 10.1371/journal.pone.0001698. View

Zhuge Y, Lagman J, Ansenberger K, Mahon C, Daikoku T, Dey S . CYP1B1 expression in ovarian cancer in the laying hen Gallusdomesticus. Gynecol Oncol. 2008; 112(1):171-8. PMC: 2741324. DOI: 10.1016/j.ygyno.2008.09.026. View

10.

Wang W, Zhou Z, Zhao W, Huang Y, Tang R, Ying K . Molecular cloning, mapping and characterization of the human neurocalcin delta gene (NCALD). Biochim Biophys Acta. 2001; 1518(1-2):162-7. DOI: 10.1016/s0167-4781(00)00290-6. View

11.

Burger R . Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol. 2007; 25(20):2902-8. DOI: 10.1200/JCO.2007.12.1509. View

12.

Skirnisdottir I, Sorbe B . Prognostic impact of body mass index and effect of overweight and obesity on surgical and adjuvant treatment in early-stage epithelial ovarian cancer. Int J Gynecol Cancer. 2007; 18(2):345-51. DOI: 10.1111/j.1525-1438.2007.01013.x. View

13.

Darcy K, Birrer M . Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol. 2010; 117(3):429-39. PMC: 2877379. DOI: 10.1016/j.ygyno.2010.01.048. View

14.

Dawson J, Timpson P, Kalna G, Machesky L . Mtss1 regulates epidermal growth factor signaling in head and neck squamous carcinoma cells. Oncogene. 2011; 31(14):1781-93. PMC: 3245856. DOI: 10.1038/onc.2011.376. View

15.

Liu K, Wang G, Ding H, Chen Y, Yu G, Wang J . Downregulation of metastasis suppressor 1(MTSS1) is associated with nodal metastasis and poor outcome in Chinese patients with gastric cancer. BMC Cancer. 2010; 10:428. PMC: 2928798. DOI: 10.1186/1471-2407-10-428. View

16.

Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S . BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009; 10(11):R130. PMC: 3091323. DOI: 10.1186/gb-2009-10-11-r130. View

17.

Resnick K, Alder H, Hagan J, Richardson D, Croce C, Cohn D . The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2008; 112(1):55-9. DOI: 10.1016/j.ygyno.2008.08.036. View

18.

Elattar A, Bryant A, Winter-Roach B, Hatem M, Naik R . Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011; (8):CD007565. PMC: 6457688. DOI: 10.1002/14651858.CD007565.pub2. View

19.

Irizarry R, Hobbs B, Collin F, Beazer-Barclay Y, Antonellis K, Scherf U . Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2):249-64. DOI: 10.1093/biostatistics/4.2.249. View

20.

Judson P, Geller M, Bliss R, Boente M, Downs Jr L, Argenta P . Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecol Oncol. 2003; 91(2):389-94. DOI: 10.1016/j.ygyno.2003.08.004. View